Glucoraphanin Pure.

Glucoraphanin is the intact glucosinolate that is hydrolysed to sulforaphane, the active isothiocyanate. Supplying both means one form acts immediately while the other is converted in the gut.

Conversion of glucoraphanin depends on the plant enzyme myrosinase, which is carried in broccoli sprout material. Pairing an isolated glucosinolate with myrosinase-active sprout powder raises the share that becomes sulforaphane rather than passing through unconverted.

Ascorbate acts as a cofactor for myrosinase and steers hydrolysis toward the isothiocyanate rather than the inactive nitrile. Adequate ascorbate in the same dose raises sulforaphane yield from the same amount of glucoraphanin.

Sulforaphane drives Nrf2-linked transcription of thioredoxin reductase and glutathione peroxidase, both of which incorporate selenium at their active site. Without adequate selenium the induced message cannot become working enzyme.

Isothiocyanates are handled by glutathione S-transferase conjugation and leave the body as mercapturic acids, so glutathione supply sets the pace of handling. Sulforaphane in turn raises the enzymes that make glutathione, so the two move together.

Isothiocyanates react quickly with free thiol groups, and a large simultaneous dose of N-acetyl cysteine can bind the isothiocyanate in the gut lumen before it is taken up. Separating the two by a few hours keeps the cysteine donor role without the direct adduct forming early.

Glucosinolate breakdown also yields thiocyanate, which competes with iodide at the sodium iodide symporter. A high crucifer load alongside a low iodine intake lowers thyroid iodide uptake, so the two are usually kept in balance.

Both compounds modify cysteine residues on Keap1 and release Nrf2 to the nucleus. Acting on the same switch from two chemistries gives a fuller induction of phase II enzymes than either alone.

Curcumin is an electrophile that also acts on Keap1 to raise Nrf2 signalling. Formulators combine it with glucoraphanin so the same antioxidant response element programme is engaged by two different agents.

DIM comes from a different crucifer glucosinolate and works mainly through aryl hydrocarbon receptor signalling and phase I enzyme balance, while glucoraphanin drives phase II. The pair covers both halves of the metabolising sequence.

Cysteine availability sets the rate of glutathione synthesis, and glutathione is what conjugates the isothiocyanate for export. Adequate cysteine keeps the conjugation step from becoming the bottleneck.

When no plant myrosinase is present, the thioglucoside bond in glucoraphanin is cleaved by bacterial thioglucosidase activity in the colon. That step is what releases sulforaphane, so the composition of a person's gut community sets how much conversion happens. Colonising or supporting that community is the reason probiotics are paired with purified glucoraphanin. How much extra sulforaphane appears varies between people and is not fixed by a dose.

Several colonic genera carry enzymes that hydrolyse glucosinolates to isothiocyanates. Pairing a defined strain with glucoraphanin is an attempt to make that release less dependent on whichever bacteria a person already carries. Strain-level conversion capacity differs, so the pairing is a mechanism-led choice rather than a measured yield.

Lactic acid bacteria have been shown in fermentation work to hydrolyse glucosinolates toward isothiocyanates. In a formula this is the same logic as any co-delivered converting organism: supply the enzyme activity that purified glucoraphanin lacks. The amount released in a human gut has not been quantified for any single strain.

Fermentable fibre feeds the saccharolytic bacteria that also carry glucosinolate-hydrolysing activity. The pairing is indirect: the fibre does not touch glucoraphanin, it shifts the community that acts on it. This is a mechanistic rationale, not a measured increase in sulforaphane.

Resistant starch reaches the colon intact and is fermented by the same broad bacterial groups implicated in glucosinolate hydrolysis. Mouse work on cooked broccoli found that the cecal community and the microbial handling of glucoraphanin move together, which is the basis for pairing a fermentable substrate with the glucosinolate. Animal data, and a mechanism rather than a human outcome.

Sulforaphane released from glucoraphanin raises transcription of glutathione synthesis and conjugation enzymes through the Nrf2 pathway. Glycine is one of the three amino acids the tripeptide is built from, so the substrate has to be available for the induced enzymes to work with. Standard biochemistry, not a combination trial.

Glutamine supplies the glutamate arm of glutathione. Where Nrf2 signalling has raised the capacity of glutamate cysteine ligase, the pathway still runs on delivered precursors. This is a substrate relationship and says nothing about how much glutathione any given dose produces.

Glutathione reductase is a flavoenzyme that needs FAD, made from riboflavin, to return oxidised glutathione to its reduced form. The recycling loop matters as much as the synthesis step that sulforaphane signalling upregulates. Textbook cofactor biochemistry.

Glutathione reductase spends NADPH, whose nicotinamide backbone traces to niacin. Induced antioxidant enzymes draw on that reducing equivalent pool continuously. A cofactor supply relationship, not an effect claim.

Glucosinolate breakdown feeds sulfur into the body's sulfur-handling routes, and sulfite oxidase, a molybdoenzyme, sits on the terminal step of sulfur amino acid catabolism. Adequate molybdenum is what keeps that enzyme functional. The link is pathway-level biochemistry rather than a tested pairing.

Both compounds are described as activators of Nrf2-driven antioxidant response element transcription, by different chemistry: sulforaphane through cysteine modification of Keap1, quercetin through redox and kinase effects. Formulas pair them for overlapping signalling. Overlap on a pathway is not the same as an additive effect in people.

Resveratrol is reported to act on the same antioxidant response element programme that sulforaphane induces. The pairing is mechanistic and common in formulation. No combination trial supports a numeric additive claim.

Catechins and isothiocyanates both feature in the Nrf2 activator literature, and both are handled by phase II conjugation. Co-formulation rests on that shared route. Whether the two together move any human marker further than either alone has not been shown.

Sulforaphane works indirectly, by raising the cell's own antioxidant enzyme capacity, while tocopherol works directly in membranes. The two occupy different compartments, which is why they are often placed in the same formula. This is a rationale for pairing, not a measured combined effect.

Charcoal binds a wide range of small organic molecules in the gut lumen without selectivity. Taken in the same window as a glucosinolate, it would be expected to reduce how much reaches the sites of conversion. Separating intake in time is the ordinary way this is handled.